Southeastern Chemical Biology and Drug Design Symposium
Featuring cutting-edge research talks on the frontiers of chemical biology, drug discovery and development, and molecular medicine.
The Southeastern Chemical Biology and Drug Design Symposium will focus on the research frontiers of chemical biology, drug discovery and development, and molecular medicine and include cutting-edge research talks and poster presentations by a diverse group of faculty, post-doctoral scholars, graduate and undergraduate students.
Important Deadlines
- August 7: Abstract Submission Deadline for podium and poster presentation consideration - Submit Here
- September 8: Registration Deadline (required for all attendees) - Register Here
View sponsorship opportunities
Symposium Agenda
- 7:30 a.m. Registration/Breakfast
- 8:20 a.m. Opening Remarks and Welcome
- 8:30 a.m. Session One - 5 speakers
- 10:10 a.m. Break
- 10:40 a.m. Session Two - 5 speakers
- 12:20 p.m. Lunch
- 1:30 p.m. Session Three - 4 speakers
- 2:50 p.m. Break
- 3:10 p.m. Keynote Presentation - "A Novel Chemical Biology Platform for Deubiquitylases" - Sara Buhrlage, Harvard Medical School
- 4:30 p.m. Poster Session and Networking Reception
- 6:30 p.m. Adjourn
Keynote Lecture:
Sara Burlage
Associate Professor
Dana-Farber Cancer Institute department of Cancer Biology
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School
ABSTRACT
Deubiquitylases (DUBs) are a large family of enzymes that remove ubiquitin or ubiquitin chains from substrate proteins. Similar to other components of the UPS, DUBs have been associated with disease and pursued as drug targets. Despite enthusiasm around targeting DUBs both with inhibitors as well as DUBTACs, there remain unanswered fundamental questions around substrates and substrate scope as well as how DUBs work at a detailed mechanistic level. The overarching goal of our lab is to develop chemical tools that can be deployed to study basic function and translational potential of DUBs. Our platform integrates DUB library synthesis, medicinal chemistry, biochemistry, high-throughput screening, chemoproteomics, chemical genomics, structural biology, target validation and cancer biology. I will discuss recent discoveries enabled by our platform including new mechanism-of-action ligands for DUBs and their study in rare disease as well as new insights into DUB interplay with other components of the UPS.
BIO
Sara Buhrlage is an Associate Professor holding joint appointments in the Dana-Farber Cancer Institute department of Cancer Biology and the Harvard Medical School department of Biological Chemistry and Molecular Pharmacology. Buhrlage is a leader in harnessing deubiquitylases (DUBs) as emergent drug targets, where her lab has pioneered new approaches for interrogating DUB function, new insights into the chemical tractability of DUBs, and mapping the therapeutic potential of DUBs in cancer. In addition to research, she is dedicated to graduate education, holding leadership roles in multiple graduate programs and teaching graduate level courses. More recently, she has become involved in biotech and company creation as a scientific founder of Entact Bio. Buhrlage earned a Doctor of Philosophy in organic chemistry from the University of Michigan and completed a post-doctoral fellowship at the Broad Institute.